Cibotii Rhizoma extract protects rat dorsal root ganglion neurons against H2O2-induced oxidative stress Authors: Hyunseong Kim, Jin Young Hong, Changhwan Yeo, Hyun Kim, Wan-Jin Jeon, Junseon Lee, Yoon Jae Lee, Eugene Huh, In-Hyuk Ha Published: 2025 ABSTRACT AbstractBackgroundDorsal root ganglion (DRG) neurons are particularly susceptible to oxidative injury, which contributes to neuronal apoptosis and altered pain signaling. Oxidative stress in DRG neurons plays a pivotal role in the onset and maintenance of pain hypersensitivity under pathological conditions. We aimed to investigate the neuroprotective effects of Cibotii Rhizoma (CR) in rat DRG neurons subjected to H₂O₂-induced oxidative stress.MethodsPrimary DRG neurons were isolated from 5-week-old Sprague–Dawley rats and cultured under short-term and long-term protocols. Cells were treated with CR (10–400 µg/mL) and exposed to H₂O₂. Cell viability was assessed by Cell Counting Kit-8 assay, and antioxidant effects were evaluated via DCFDA and MitoSOX-based flow cytometry and immunocytochemistry. Neurite outgrowth was analyzed using Tuj1 staining, and pain-related markers (CGRP, IB4, TRPV1, and substance P) were examined in long-term cultures. Molecular docking was performed to assess TRPV1 binding affinity of CR-derived compounds.ResultsCR showed no cytotoxicity up to 400 µg/mL and significantly protected DRG neurons from 10 µg/mL against H2O2-induced oxidative stress. CR promoted neurite outgrowth and reduced oxidative stress markers (DCFDA⁺ and MitoSOX⁺ cells) within the 10–50 µg/mL concentration range, dose-dependently. Pain-related proteins (CGRP, IB4, TRPV1) and substance P were upregulated by H₂O₂ but significantly decreased following CR treatment. Molecular docking identified several CR-derived compounds with high binding affinity to TRPV1 may attenuate pain signaling pathways.ConclusionsCR confers neuroprotection against oxidative stress in DRG neurons and modulates pain-related signaling pathways, highlighting its potential as a therapeutic agent for oxidative stress-induced neuropathic pain.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12906-025-05182-5.Keywords: DRG neuron, Cibotii rhizoma, Oxidative stress, Hydrogen peroxide, Neuropathic pain Background Neuropathic pain is a debilitating chronic condition often associated with nerve injury and inflammation. It is characterized by pain hypersensitivity including allodynia and hyperalgesia [1, 2]. Among the various mechanisms implicated in its development, oxidative stress has emerged as a key contributor. Among different reactive oxygen species (ROS), hydrogen peroxide (H₂O₂) is particularly relevant because it is membrane-permeable and relatively long-lived, enabling diffusion to both mitochondrial and cytosolic targets and thereby modulating redox-sensitive signaling pathways involved in neuronal injury [3]. Importantly, peripheral nerve injury and neuropathic conditions are associated with elevated H₂O₂ in pain-relevant tissues: Amplex Red assays detect increased peroxide levels in dorsal root ganglia (DRG) and sciatic nerves in Nox4-dependent neuropathic pain models [4], peripheral nerve stumps exhibit higher H₂O₂ concentrations following injury [5], and chronic compression models likewise report raised H₂O₂ in DRG [6]. On this basis, we used exogenous H₂O₂ in primary DRG neurons to establish a controlled oxidative-injury model that recapitulates key redox-driven neuronal stress mechanisms relevant to neuropathic pathophysiology. DRG neurons, which relay sensory information from the periphery to the central nervous system, are particularly vulnerable to oxidative damage due to their high metabolic activity and relatively limited antioxidant capacity [7, 8]. Emerging evidence indicates that oxidative injury in DRG neurons plays a pivotal role in the initiation and maintenance of pain hypersensitivity under pathological conditions [9, 10]. In particular, oxidative stress has been shown to increase the expression of pain-related mediators such as calcitonin gene-related peptide (CGRP), transient receptor potential vanilloid 1 (TRPV1), isolectin B4 (IB4), and substance P, further sensitizing nociceptive signaling [11, 12]. Recently, increasing attention has been directed toward natural products as promising sources of novel therapeutic agents for the treatment of neuropathic pain. Many plant-derived compounds possess antioxidant, anti-inflammatory, and neuroprotective properties, making them attractive candidates for modulating complex pain pathways with potentially fewer side effects than conventional analgesics [13]. Moreover, natural compounds often act on multiple molecular targets, such as ion channels, inflammatory mediators, and oxidative stress pathways, which are intricately involved in the pathophysiology of chronic pain [14]. In addition to its well-documented anti-inflammatory, bone-protective, and antioxidant properties, Cibotii Rhizoma (CR) has also been traditionally used to treat musculoskeletal disorders accompanied by pain [15–19]. Recent studies have further demonstrated its analgesic and antinociceptive activities. For example, both crude and processed preparations of Cibotium barometz were shown to reduce nociceptive responses in rodent models of inflammatory and chronic pain, while polysaccharides isolated from CR attenuated pain hypersensitivity through modulation of inflammatory pathways [20]. In addition, phytochemical analyses have identified protocatechuic acid as one of the active components, which is known to exhibit potent analgesic and anti-inflammatory effects [21, 22]. These findings support the traditional use of CR for alleviating pain, limb weakness, and numbness, and provide a strong rationale for investigating its potential therapeutic role in pain-related musculoskeletal disorders [19]. However, despite these traditional and preclinical indications, systematic investigations of CR’s effects on sensory neurons, including its potential neuroprotective actions and modulation of nociceptive signaling pathways, remain lacking. In particular, studies examining its influence on neuronal function and pain-associated molecular markers have not been conducted. Therefore, this study aims to address this gap and provide novel evidence supporting the pain-relieving potential of CR. Materials and methods Preparation of CR extract Dried CR (Lot No. GM011-2000202, origin: Vietnam) was obtained from Green M.P. Pharm. Co., Ltd. (Seongnam, Republic of Korea) and stored in a desiccator until use. For extraction, 30 g of the dried material was immersed in 300 mL of distilled water and subjected to thermal extraction at 100°C for 3 h. Following natural cooling to room temperature (25 ± 1°C), the extract was filtered using HA-030 filter paper (Hyundai Micro, Seoul, Republic of Korea). The filtrate was stored at − 70 °C deep freezer and then lyophilized, with a yield of 6.9%. For experiments, the lyophilized extract was reconstituted in phosphate-buffered saline (PBS; Gibco BRL, Grand Island, NY, USA) to prepare a 10 mg/mL stock solution. Isolation and primary culture of rat DRG neurons Primary DRG neurons were isolated from 5–6-week-old male Sprague–Dawley rats (KOATECH, Pyeongtaek, Korea) in accordance with protocols approved by the Jaseng Animal Care and Use Committee (Approval No. JSR-2023-02-002-A-002). Following CO₂ euthanasia (20–30% chamber volume per minute) and transcardial perfusion with cold Hank’s balanced salt solution containing heparin, DRGs were isolated from spinal segments C2–L7. The surrounding connective tissue and nerve roots were carefully removed under a dissecting microscope. Isolated DRGs were subjected to enzymatic digestion using papain, followed by collagenase and dispase, then gently triturated to obtain a single-cell suspension. After preplating to minimize non-neuronal adhesion, the cells were transferred to poly-D-lysine/laminin-coated plates and maintained in neurobasal medium supplemented with B27 (Thermo Fisher Scientific, Waltham, MA, USA), GlutaMAX (Thermo Fisher Scientific), penicillin/streptomycin (Thermo Fisher Scientific), and brain-derived neurotrophic factor. All procedures were performed under sterile conditions and optimized for neuronal survival, oxidative stress analysis, and neurite outgrowth. For detailed methodology including enzyme concentrations, incubation times, and dissociation steps, refer to the previously described protocol by Davaa et al. [11]. Experimental timeline Primary DRG neurons were subjected to in vitro experiments based on two distinct culture timelines designed to assess both acute oxidative responses and long-term pain-related molecular changes. In the short-term protocol, DRG neurons were cultured and stabilized for 2 days. On day 3, oxidative stress was induced by treatment using 100 µM H₂O₂, followed immediately by the addition of CR at concentrations of 10, 25, and 50 µg/mL. Cells were then co-incubated with H₂O₂ and CR for 24 h without H₂O₂ removal. This experimental protocol was used to assess cell viability, neurite outgrowth (Tuj1 immunocytochemistry), and intracellular oxidative stress levels using 2′,7′-dichlorofluorescin diacetate (DCFDA) and MitoSOX through both flow cytometry and immunocytochemical analysis. In addition, to evaluate the effects of CR extract alone on neurite outgrowth, DRG neurons were treated with CR at the indicated concentrations one day after seeding, and samples were collected 24 h after treatment for analysis. In the long-term protocol, DRG neurons were maintained in culture for 10 days to allow for neuronal maturation. On day 11, cells were treated with H₂O₂, followed by CR at the same concentrations. After 24 h of cotreatment, cells were analyzed for pain-related markers, including CGRP, IB4, and TRPV1, using immunocytochemistry. Additionally, substance P levels in the culture medium were measured by enzyme-linked immunosorbent assay (ELISA) to further evaluate nociceptive activity. The experimental groups were defined as follows: (1) untreated control (Blank), (2) H₂O₂ only (H₂O₂), (3) CR 10 µg/mL + H₂O₂ (CR10), (4) CR 25 µg/mL + H₂O₂ (CR25), and (5) CR 50 µg/mL + H₂O₂ (CR50). Cell viability assay Cell viability was evaluated using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) following standard procedures. DRG neurons isolated from 30 tissue samples were seeded into 96-well plates and cultured under standard conditions. To determine the optimal concentration of CR that enhances neuronal survival without exhibiting cytotoxicity, cells were treated with a range of CR concentrations (10, 25, 50, 100, 200, and 400 µg/mL) either alone or in combination with 100 µM H₂O₂. After 24 h of treatment, 10% (v/v) reagent solution was added to each well and incubated for an additional 2–3 h. Absorbance was measured at 450 nm using a microplate reader (Epoch, BioTek Instruments, USA), and the results were expressed as a percentage of viable cells relative to the blank group. Flow cytometric analysis of intracellular and mitochondrial ROS Intracellular ROS levels were measured using DCFDA (Sigma–Aldrich, St. Louis, MO, USA), while mitochondrial superoxide production was assessed using MitoSOX™ Red (Thermo Fisher Scientific), according to the manufacturers’ protocols. For DCFDA staining, a 5 mM stock solution was prepared by dissolving 9.3 mg of DCFDA in 3.8 mL of anhydrous dimethyl sulfoxide. Cultured DRG neurons were harvested, washed with PBS, and incubated with 10 µM DCFDA working solution in the dark at 37°C for 30 min. After incubation, the cells were washed and resuspended in PBS for flow cytometric analysis. For mitochondrial ROS detection, cells were incubated with 5 µM MitoSOX Red reagent in Hank’s Balanced Salt Solution (HBSS) at 37°C for 10 min in the dark. After staining, cells were washed twice with HBSS and resuspended in 100 µL of PBS. All samples were analyzed using a BD Accuri™ C6 Plus Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA), and a minimum of 20,000 events per sample were recorded. The percentage of DCFDA or MitoSOX-positive cells was quantified based on fluorescence intensity and compared to the H₂O₂ group. Data were analyzed using FlowJo software (BD Biosciences). MitoSOX staining For mitochondrial ROS visualization, primary DRG neurons were seeded on glass coverslips placed in 24-well plates and cultured according to the short-term experimental timeline. On the day of analysis, live cells were gently washed twice with prewarmed HBSS containing Ca²⁺ and Mg²⁺ (Gibco BRL), and incubated with 5 µM MitoSOX™ Red mitochondrial superoxide indicator (Thermo Fisher Scientific) and Hoechst (Thermo Fisher Scientific) at 37°C for 10 min in the dark. Following staining, cells were washed with HBSS to remove unbound dye, and the coverslips were mounted onto microscope slides using DAKO fluorescence mounting medium (Agilent Technologies, Santa Clara, CA, USA). Images were acquired using a confocal laser scanning microscope (Eclipse C2 Plus, Nikon, Japan) at 10× magnification under identical exposure settings for all groups. Quantification of fluorescence intensity was performed using ImageJ software (NIH), and the relative MitoSOX signal was expressed as mean fluorescence intensity per field of view. Immunocytochemistry Primary cultured DRG neurons were fixed with 4% paraformaldehyde (Biosesang, Yongin, Korea) for 30 min at 25 ± 1℃, followed by three washes with PBS, each for 5 min. For membrane permeabilization, cells were treated with 0.2% Triton X-100 for 10 min. Nonspecific binding was blocked by incubating cells with 2% normal goat serum for 1 h at 25 ± 1℃. Cells were then incubated overnight at 4°C with primary antibodies specific for the following markers: TUJ1 (R&D Systems, Minneapolis, MN, USA), IB4 (Sigma–Aldrich), CGRP (Sigma–Aldrich), and TRPV1 (Alomone Labs, Jerusalem, Israel). The following day, cells were incubated for 2 h at 25 ± 1℃ with fluorescein isothiocyanate-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) in the dark. After a final series of three washes with PBS, stained coverslips were mounted onto slides using fluorescence mounting medium. Fluorescence images were captured using a confocal microscope (Eclipse C2 Plus, Nikon, Japan) at either 10× or 40× magnification. To quantify neurite outgrowth, images were captured at 10× magnification using confocal microscopy with fixed acquisition settings. For each group, six wells (n = 6) in 24-well plates were analyzed, and 10 representative images were randomly acquired from the central region of each well to minimize sampling bias. Using ImageJ software (v1.53, Fiji Distribution, National Institutes of Health), total, mean, and maximum neurite lengths as well as the number of branching points were measured. For quantification of fluorescence-labeled DRG neurons, Tuj1-positive neurons were first counted to determine the total number of neurons per image. Subsequently, neurons double-labeled with IB4, CGRP, or TRPV1 were counted. The percentage of marker-positive neurons was calculated by dividing the number of double-positive neurons by the total number of Tuj1-positive neurons and multiplying by 100. Substance P quantification by ELISA The level of substance P released into the culture medium was quantified using a Substance P Parameter Assay Kit (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s instructions. DRG neurons were cultured from 55 isolated DRG tissues and maintained for 10 days. On day 11, cells were cotreated with CR and H₂O₂ at concentrations of 10, 25, and 50 µg/mL for 24 h. Following treatment, the culture supernatants were collected and centrifuged at 1,000 × g for 10 min to remove cellular debris. The clarified supernatants were used directly for ELISA analysis. Absorbance was measured at 450 nm using an Epoch microplate reader (BioTek, Winooski, VT, USA), and substance P concentrations were calculated based on the standard curve generated from known concentrations of the analyte. All samples were assayed in duplicate. Molecular docking Molecular docking was performed using the human TRPV1 tetrameric structure (PDB ID: 7LP9). The structure was selected based on comparison of the root mean square deviation (RMSD), which indicates the average atomic distance between superimposed structures and is commonly used to assess structural similarity. Specifically, the human TRPV1 structure was compared with the rat TRPV1–capsazepine complex (PDB ID: 5IS0), confirming a high degree of similarity in the predicted binding pocket (RMSD ≈ 0.7 Å). Capsazepine is a well-known synthetic TRPV1 antagonist, and its binding site in chain B was used to define the docking grid parameters [23]. A total of 22 CR-derived ligands, selected based on previously published literature [15, 24, 25], were retrieved from PubChem and converted into PDBQT format. The PDBQT file type contains atomic coordinates along with partial charges (Q) and AutoDock atom types (T), and is required for docking calculations in AutoDock-based programs. Docking simulations were conducted using AutoDock Vina, with the grid box centered at X = 130.144, Y = 114.536, Z = 127.332 (size: 25 × 25 × 25), based on the capsazepine binding site in chain B. Docking poses were visualized using PyMOL (v3.1.3) and BIOVIA Discovery Studio Visualizer, and the interactions between ligands and the receptor were analyzed using PLIP. Statistical analysis All data are expressed as the mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance, followed by Tukey’s post-hoc test, using GraphPad Prism (GraphPad Software, San Diego, CA). Significance levels were set at #p < 0.05, ##p < 0.01, ###p < 0.001, ###p < 0.0001 versus the blank group; and *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 versus the H2O2 group. Results CR protects DRG neurons from H₂O₂-induced cytotoxicity and promotes neurite outgrowth We first assessed the cytotoxicity of CR and determined its optimal concentration for neuroprotective efficacy in primary DRG neurons. CCK assay results indicated that treatment with CR alone at concentrations ranging 10–400 µg/mL did not induce cytotoxicity, as no statistically significant differences were observed compared to the blank group (Fig. 1A). Although a slight increase in cell viability was noted between 10 and 50 µg/mL, a gradual decline was observed at higher concentrations (100–400 µg/mL). In contrast, treatment with H₂O₂ alone significantly reduced cell viability compared to the blank group, confirming oxidative stress-induced cytotoxicity (Fig. 1B). Cotreatment with CR significantly restored cell viability, with all tested concentrations (10–400 µg/mL) showing statistically significant improvement relative to the H₂O₂ group. Notably, the 50 µg/mL concentration yielded the highest average viability, followed by a slight decline at higher doses, a trend consistent with CR-alone treatment. Based on these results, 10, 25, and 50 µg/mL were selected as the optimal concentrations for subsequent experiments. To further evaluate the neuroprotective potential of CR, neurite outgrowth was analyzed at the single-cell level in DRG neurons using immunocytochemistry with Tuj1 (Fig. 1C). H₂O₂ exposure markedly suppressed neurite formation and elongation compared to the blank group. CR treatment restored neurite outgrowth in a dose-dependent manner. Quantitative analysis demonstrated that maximum neurite length was significantly reduced by H₂O₂ but was restored by CR treatment, showing a significant increase at all tested concentrations (Fig. 1D). Similar trends were observed in total neurite length, mean neurite length, and branch point number, with CR at 25 and 50 µg/mL resulting in statistically significant improvement compared to the H₂O₂ group (Fig. 1E–G). CR attenuates H₂O₂-induced cytotoxicity and promotes neurite outgrowth in primary DRG neurons. A Cell viability of DRG neurons treated with CR alone at concentrations ranging 10–400 µg/mL, as assessed by the CCK assay (n = 5). B Cell viability of DRG neurons cotreated with H₂O₂ and CR (10–400 µg/mL), demonstrating the protective effects of CR against oxidative stress-induced cytotoxicity (n = 5). C Representative immunofluorescence images of DRG neurons stained with Tuj1 to assess neurite outgrowth under each treatment condition (n = 7). White scale bar = 200 μm. (D–G) Quantitative analysis of neurite morphology, including maximum neurite length (D), total neurite length (E), mean neurite length (F), and number of branch points G. All data are presented as mean ± SD. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Significance levels: ####p < 0.0001 vs. blank group; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. H₂O₂ group In addition, treatment of DRG neurons with CR alone (10, 25, and 50 µg/mL) for 24 h significantly promoted neurite outgrowth in a concentration-dependent manner compared with the untreated blank, as assessed by Tuj1 staining (Figure S1). These results indicate that CR not only enhances neuronal process extension under non-stressed conditions but also mitigates H₂O₂-induced cytotoxicity in DRG neurons, thereby exerting a neuroprotective effect through the promotion of neurite outgrowth. CR attenuates H₂O₂-induced oxidative stress in DRG neurons To investigate the antioxidant effects of CR in DRG neurons under oxidative stress conditions, intracellular and mitochondrial ROS levels were assessed using DCFDA and MitoSOX-based flow cytometry. DCFDA analysis revealed a significant increase in ROS-positive cells in the H₂O₂ group compared to the blank group, confirming oxidative stress induction (Fig. 2A, B). Notably, CR treatment significantly reduced the proportion of DCFDA-positive cells starting from the lowest concentration (10 µg/mL). MitoSOX analysis, which specifically detects mitochondrial superoxide, showed a more pronounced oxidative response (Fig. 2C, D). The percentage of MitoSOX-positive cells increased markedly from 0.45% in the blank group to 33.6% following H₂O₂ treatment. CR significantly reversed this increase in a dose-dependent manner, with the highest reduction observed in the CR50 group, where MitoSOX-positive cells decreased to 0.81%. To visualize mitochondrial oxidative damage, MitoSOX immunocytochemistry was performed. Consistent with the FACS data, H₂O₂ exposure resulted in visibly increased MitoSOX fluorescence intensity compared to the blank group (Fig. 2E, F). This enhanced signal was attenuated by CR treatment, with significant reductions in fluorescence observed from the CR10 group onward. Collectively, these findings demonstrate that CR exerts potent antioxidant effects in DRG neurons by mitigating both cytosolic and mitochondrial ROS accumulation induced by H₂O₂. CR attenuates H₂O₂-induced oxidative stress in primary DRG neurons. A, B Intracellular ROS levels in DRG neurons under each treatment condition, assessed by flow cytometry using DCFDA staining and quantified as the percentage of DCFDA-positive cells (n = 4). C, D Mitochondrial ROS levels in DRG neurons, assessed by flow cytometry using MitoSOX staining and quantified as the percentage of MitoSOX-positive cells (n = 4). E Representative immunofluorescence images of DRG neurons stained with MitoSOX to visualize mitochondrial superoxide levels under each treatment condition. F Quantification of MitoSOX fluorescence intensity (n = 6). All data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Significance levels: ####p < 0.0001 vs. blank group **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. H₂O₂ group. Scale bar = 100 μm CR mitigates pain marker expression in DRG neurons exposed to H₂O₂ Protein expressions of pain-related markers (CGRP, IB4, and TRPV1) were assessed by immunocytochemistry to evaluate the effect of CR on inflammatory and nociceptive signaling in DRG neurons. In parallel, the concentration of substance P, a neuropeptide implicated in peripheral sensitization and pain transmission, was measured in the culture medium using ELISA. H₂O₂ treatment significantly increased the expression of all three markers, indicating activation of oxidative stress-induced pain pathways. CGRP, a neuropeptide involved in inflammatory pain signaling, was markedly upregulated by H₂O₂ but significantly downregulated by CR in a dose-dependent manner (Fig. 3A, B). Similarly, IB4, a marker of non-peptidergic nociceptors, showed elevated expression following H₂O₂ exposure, which was significantly reduced by CR treatment across all tested concentrations (Fig. 3C, D). TRPV1, a key receptor for noxious thermal and chemical stimuli, also exhibited reduced immunoreactivity and a lower proportion of positive cells starting from 10 µg/mL (Fig. 3E, F). Consistent with these findings, ELISA analysis demonstrated that substance P levels were significantly elevated in H₂O₂-treated cultures (Fig. 3G). While CR10 treatment did not result in a statistically significant change, both CR25 and CR50 treatments led to significant reductions in substance P levels, indicating that CR can suppress neuropeptide-mediated nociceptive signaling under oxidative stress. Collectively, these results demonstrate that CR effectively downregulates pain-related markers and neuropeptide expression in DRG neurons, supporting its potential as a modulator of oxidative stress-induced inflammatory and nociceptive pathways. CR suppresses H₂O₂-induced expression of pain-related markers and substance P in primary DRG neurons. A, B Expression of CGRP in DRG neurons assessed by immunocytochemistry and quantified as the percentage of CGRP-positive cells under each treatment condition (n = 6). C, D Expression of IB4 in DRG neurons assessed by immunocytochemistry and quantified as the percentage of IB4-positive cells (n = 6). E, F Expression of TRPV1 in DRG neurons assessed by immunocytochemistry and quantified as the percentage of TRPV1-positive cells (n = 6). G Concentration of substance P in the culture medium measured by ELISA (n = 6). White scale bar = 100 μm. All data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Significance levels: ####p < 0.0001 vs. blank group; **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. H₂O₂ group Molecular docking predicts TRPV1 inhibition by CR-derived compounds To explore the molecular basis of CR’s potential analgesic effects, a molecular docking analysis was performed targeting the vanilloid binding pocket of the TRPV1 channel, a tetrameric ion channel involved in nociceptive and inflammatory pain signaling. The docking site was selected based on the known binding region of capsazepine, a synthetic TRPV1 antagonist, located in the transmembrane domain adjacent to the S4–S5 linker and S6 gate, which are critical for TRPV1 channel gating and calcium influx. Binding poses that avoided direct interaction with the S6 gate, unlike TRPV1 agonists such as capsaicin, were prioritized to predict antagonistic activity (Fig. 4A). Among the 22 CR-derived compounds screened, five ligands with the lowest mean binding affinities across nine docking poses were selected: Epigallocatechin, Eriodictyol, Fisetin, Chrysophanol, and Monotropein (Fig. 4B; Table 1). These ligands demonstrated predicted binding energies ranging from − 7.91 to − 7.42 kcal/mol, indicating favorable and stable interactions with TRPV1 (Fig. 4B). Epigallocatechin showed the strongest predicted affinity (− 7.91 ± 0.26 kcal/mol) and a low RMSD value (1.69 ± 1.13 Å), indicating highly consistent binding poses. Its interactions were dominated by hydrogen bonds (6.56 ± 1.88 per pose), primarily with ARG557 and GLN700, suggesting high specificity and stability at the target site. Eriodictyol displayed a comparable binding affinity (− 7.88 ± 0.25 kcal/mol) but slightly greater pose variability (RMSD 2.87 ± 2.41 Å), indicating reduced conformational consistency compared to Epigallocatechin. Both compounds primarily interacted via hydrogen bonding rather than hydrophobic contacts. Chrysophanol, although ranked fourth in binding affinity (− 7.61 ± 0.26 kcal/mol), exhibited the most consistent binding conformation (RMSD 1.55 ± 0.89 Å). Its interactions were more hydrophobic in nature, involving residues such as LEU553, while limited hydrogen bonding was observed, primarily with THR550. This suggests that hydrophobic stabilization contributed significantly to its docking stability. Fisetin and Monotropein exhibited additional interaction features beyond hydrogen bonding. Fisetin (− 7.69 ± 0.34 kcal/mol, RMSD 3.44 ± 1.44 Å) formed π-cation interactions with ARG557 and occasional salt bridges, enhancing its binding despite moderate pose variability. In contrast, Monotropein (− 7.42 ± 0.37 kcal/mol) showed the highest average number of hydrogen bonds (6.56 ± 1.88 per pose) and frequent salt bridge formation with ARG557, suggesting a strong electrostatic component to its binding. Overall, these top-performing ligands consistently engaged with residues in the vanilloid binding pocket of TRPV1, particularly ARG557, GLN700, and SER512, through hydrogen bonds, hydrophobic contacts, and polar interactions. Notably, none of the selected compounds interacted with S6 gate residues, suggesting potential to inhibit TRPV1 activation without promoting channel opening. These findings support the hypothesis that CR-derived compounds may exert analgesic effects via TRPV1 antagonism through stable and selective binding within the transmembrane domain. Molecular docking predicts TRPV1 inhibition by CR-derived compounds. A Structural representation of the TRPV1 tetramer in complex with ligands. Left: Side view of the TRPV1 transmembrane (TM) region; Right: Top-down view of the same structure. Each subunit of the tetrameric TRPV1 contains a Vanilloid binding pocket located within the TM region. All four pockets (indicated by red circles) are potential inhibitor binding sites. The arrow indicates the specific site used for molecular docking simulations. (B) Binding affinity analysis of 22 CR-derived ligands using molecular docking. The five representative compounds, epigallocatechin, eriodictyol, fisetin, chrysophanol, and monotropein, were selected based on the lowest average binding affinity values across the top nine docking poses Table 1Molecular Docking detailed informationLigandBinding energy (kcal/mol)Ki (µM)pKiRMSD(Å)Amino acid residueHydrogen bond countEpigallocatechin−7.91 ± 0.261.68 ± 2.575.80 ± 0.191.69 ± 1.13TYR511 SER512 THR550 ASN551 LEU553 TYR554 THR556 ARG557 ALA566 GLU570 GLN7004.89 ± 1.17Eriodictyol−7.88 ± 0.251.79 ± 0.675.78 ± 0.182.87 ± 2.41ARG499 ASP509 SER512 GLU513 THR550 ASN551 TYR554 THR556 ARG557 GLY563 GLN7006.00 ± 1.00Fisetin−7.69 ± 0.342.65 ± 1.575.64 ± 0.253.44 ± 1.44TYR495 ARG499 TYR511 SER512 GLU513 THR550 ASN551 LEU553 TYR554 THR556 ARG557 ALA566 GLU570 GLN7007.11 ± 2.62Chrysophanol−7.61 ± 0.262.82 ± 1.165.58 ± 0.191.55 ± 0.89THR550 ASN551 LEU553 ARG557 ALA566 GLU5707.00 ± 2.55Monotropein−7.42 ± 0.374.20 ± 2.295.45 ± 0.272.42 ± 1.21ARG409 TYR495 VAL508 ASP509 TYR511 SER512 GLU513 THR550 ASN551 LEU553 TYR554 THR556 ARG557 ALA566 GLU570 LYS571 GLN7008.89 ± 2.09 Molecular Docking detailed information Discussion This study demonstrates that CR exerts neuroprotective and antioxidant effects in primary rat DRG neurons exposed to H₂O₂-induced oxidative stress. Our findings indicate that CR preserves neuronal viability and promotes neurite outgrowth, reduces intracellular and mitochondrial ROS levels, and downregulates pain-related markers under oxidative stress conditions. Moreover, molecular docking analysis identified multiple CR-derived phytochemicals with potential TRPV1 antagonistic activity, providing mechanistic insight into the observed nociceptive modulation. Oxidative stress is a well-established contributor to peripheral neuropathy and pain hypersensitivity. DRG neurons, due to their high metabolic demands and limited antioxidant capacity, are particularly vulnerable to oxidative insults [26, 27]. In our study, H₂O₂ exposure significantly reduced DRG neuron viability and impaired neurite growth, mimicking oxidative injury relevant to neuropathic conditions. CR effectively counteracted these effects, with maximal protection observed at 50 µg/mL, suggesting that CR components may stabilize neuronal integrity and promote regenerative capacity under oxidative conditions. Interestingly, CR alone also promoted neurite outgrowth in DRG neurons under non-stressed conditions in a concentration-dependent manner. Although this effect does not directly indicate neuroprotection, which typically refers to the preservation of neuronal structure and function under harmful stimuli, it suggests that CR may exert direct modulatory actions on neuronal growth and differentiation pathways, rather than acting solely as a passive protective agent. Such neuritogenic activity implies that CR might influence intrinsic neurotrophic signaling mechanisms, potentially contributing to both neuronal maintenance and regeneration. CR also exhibited a strong antioxidant effect by decreasing both cytosolic (DCFDA) and mitochondrial ROS (MitoSOX) levels in H₂O₂-exposed DRG neurons. Mitochondrial reactive oxygen species play a dual role in neuronal cells acting as essential signaling molecules under physiological conditions but contributing to oxidative damage, apoptosis, and pain sensitization when produced in excess [28]. The observed reduction in mitochondrial ROS suggests that CR may help preserve mitochondrial homeostasis under oxidative stress. Although these results point toward potential mitochondrial protective effects, this study did not directly assess mitochondrial function. Further investigations involving mitochondrial membrane potential assays, ATP production measurements, or the expression analysis of mitochondrial biogenesis-related markers such as OPA1, TFAM, and PGC-1α are needed to confirm whether CR actively preserves or enhances mitochondrial function. In addition to neuroprotection, CR significantly attenuated the expression of key pain-related markers CGRP, IB4, and TRPV1 upregulated by oxidative stress. These molecules are functionally linked to nociceptor activation, neuroinflammation, and sensitization [29, 30]. Furthermore, substance P is a neuropeptide critically involved in nociceptive signal transmission, facilitating the relay of pain signals from peripheral sensory neurons to the central nervous system. Its expression is often upregulated in response to inflammatory and oxidative stress stimuli and is considered a central mediator of neurogenic inflammation and peripheral sensitization. In the present study, CR treatment significantly suppressed substance P levels, particularly at higher concentrations, reinforcing its potential role in modulating peripheral nociceptive signaling. Substance P amplifies nociceptive transmission by activating neurokinin-1 (NK1) receptors on sensory neurons, which sensitize TRPV1 channels through PKC-dependent phosphorylation [31]. Conversely, TRPV1 activation by noxious stimuli induces calcium (Ca²⁺) influx that promotes further substance P release from sensory nerve terminals, establishing a positive feedback loop that enhances peripheral sensitization [32]. Under oxidative stress, reactive oxygen species directly sensitize TRPV1 (e.g., via cysteine oxidation) [33]. which further amplifies this Substance P–TRPV1 feed-forward cascade and contributes to chronic pain states. In the present study, CR treatment significantly reduced substance P levels in the culture supernatant of H₂O₂-stimulated DRG neurons, as demonstrated by ELISA. Considering the role of Substance P in TRPV1 sensitization, these findings suggest that CR may attenuate peripheral nociceptive signaling under oxidative stress, at least in part, by interrupting the Substance P–TRPV1 positive feedback loop. The molecular docking analysis identified five CR, epigallocatechin, eriodictyol, fisetin, chrysophanol, and monotropein, with predicted TRPV1-binding activity. Although docking provides a structural basis for potential ligand–receptor interactions, the downstream cellular mechanisms linking this binding to the observed suppression of H₂O₂-induced TRPV1 upregulation in DRG neurons require careful consideration. Several of these compounds have documented antinociceptive or TRPV1-modulatory effects, supporting the functional relevance of their predicted interactions. Eriodictyol acts as a TRPV1 antagonist, inhibiting [³H]-resiniferatoxin binding and capsaicin-induced Ca²⁺ influx with nanomolar potency, and suppressing TRPV1-mediated nocifensive behaviors in rodents [34]. Epigallocatechin and its oxidative derivatives have been shown to directly interact with TRPV1 and TRPA1 channels in DRG neurons, in some cases functioning as partial agonists, indicating context-dependent modulation of nociceptive signaling [35]. Fisetin exhibits robust antinociceptive effects in neuropathic pain models, primarily through antioxidant, spinal GABAergic, and serotonergic (5-HT/5-HT₇ receptor–mediated) mechanisms, although direct TRPV1 interaction has not yet been demonstrated [36, 37]. Chrysophanol shows in silico TRPV1 binding affinity but limited functional validation [38], while Monotropein demonstrates analgesic and anti-inflammatory properties primarily via NF-κB inhibition rather than direct TRPV1 modulation [39]. Taken together, these findings suggest that the interaction of these compounds with TRPV1 may contribute to the downregulation of receptor expression observed in DRG neurons exposed to oxidative stress. One plausible mechanism involves ligand-induced receptor desensitization followed by internalization and degradation, a well-established regulatory pathway for TRPV1 [40, 41]. Prolonged or repeated TRPV1 activation, as can occur with partial agonists such as oxidized epigallocatechin derivatives, leads to Ca²⁺-dependent desensitization, clathrin-mediated endocytosis, and in some cases lysosomal degradation, ultimately resulting in reduced surface receptor density [35]. Conversely, antagonists like eriodictyol may stabilize TRPV1 in inactive conformations and prevent H₂O₂-induced sensitization and membrane recruitment, thereby attenuating receptor upregulation [34]. In addition to receptor trafficking, indirect regulatory mechanisms may also contribute. Compounds such as fisetin and monotropein possess potent antioxidant and anti-inflammatory activities, which can suppress transcriptional pathways (e.g., NF-κB, MAPKs) known to drive TRPV1 upregulation under oxidative or inflammatory stress [37, 39]. Furthermore, modulation of intracellular signaling pathways, including GABAergic and serotonergic systems as reported for fisetin, may indirectly influence nociceptive neuron excitability and receptor expression dynamics [36]. Finally, it is important to consider that CR is a complex phytochemical mixture, and synergistic interactions among both major and minor constituents may enhance TRPV1 modulation. Beyond the five docking-identified compounds, other CR components could influence receptor regulation by altering membrane lipid environments, post-translational modifications, or scaffolding protein interactions that govern TRPV1 trafficking and stability. Such multifactorial mechanisms may collectively underlie the robust suppression of H₂O₂ induced TRPV1 upregulation observed in DRG neurons treated with CR. Although bioactive candidate compounds were identified through in silico docking, their actual binding affinity and TRPV1 inhibitory effects need to be further validated using experimental approaches that reflect antinociceptive mechanisms. We also acknowledge that the current evidence linking TRPV1 antagonism to the observed in vitro effects is primarily based on computational analyses. To further clarify the TRPV1-mediated antinociceptive effects of CR extract in DRG neurons, future studies should include rigorous functional evaluations, such as calcium imaging with capsaicin stimulation or TRPV1 knockdown, to provide direct experimental validation. Additionally, while the H₂O₂-based oxidative stress model is useful for mimicking oxidative damage, it has limitations in fully reproducing the complex neuroimmune interactions observed in neuropathic pain. Therefore, to comprehensively evaluate the analgesic efficacy and pharmacokinetic properties of CR and enhance its clinical applicability, further studies using in vivo neuropathic pain models such as chronic constriction injury or partial sciatic nerve ligation are necessary. Conclusion Collectively, our findings suggest that CR protects DRG neurons from oxidative stress-induced damage and modulates pain-related protein expression. The observed antioxidant effect, coupled with predicted TRPV1 antagonism, support the therapeutic potential of CR as a natural agent for managing oxidative stress-related neuropathic pain. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements Not applicable. Abbreviations Reactive oxygen species Calcitonin gene-related peptide Transient receptor potential vanilloid 1 Isolectin B4 Dorsal root ganglion Cibotii Rhizoma Enzyme-linked immunosorbent assay Phosphate-buffered saline Hydrogen peroxide 2’,7’-dichlorofluorescin diacetate Hank’s Balanced Salt Solution Authors’ contributions I-HH: funding acquisition, project administration, resources, supervision, writing–review and editing. HK: conceptualization, data curation, formal analysis, investigation, methodology, software, visualization, writing–original draft. JYH: formal analysis, validation, visualization, writing–review and editing. CY: formal analysis, methodology, validation. W-JJ: formal analysis, methodology, validation. Hyun Kim: formal analysis, methodology, visualization. JL: formal analysis, visualization. YJL: validation, writing–review and editing, EH: validation, writing–review and editing. All authors read and approved the final manuscript. Funding This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number RS-2024-00443853). The funding body had no involvement in the design of the study, data collection, analysis, interpretation, report writing, or the decision to submit the manuscript for publication. Data availability The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author. Declarations Ethics approval and consent to participate This study was approved by the Jaseng Animal Care and Use Committee (Approval No. JSR-2023-02-002-A-002). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author.